[{"id":"bd316351-bd1c-4019-8db7-db0943251c71","acronym":"","url":"https://clinicaltrials.gov/study/NCT03364400","created_at":"2021-01-17T17:22:02.370Z","updated_at":"2024-07-02T16:35:48.034Z","phase":"Phase 1","brief_title":"Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03364400","lead_sponsor":"Vigeo Therapeutics, Inc.","biomarkers":" BRCA • CD36","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA • CD36"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VT1021"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 11/28/2017","start_date":" 11/28/2017","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-05-15"}]